Holt Andrew, Berry Mark D, Boulton Alan A
ALviva Biopharmaceuticals Inc, 218-111 Research Drive, Saskatoon, Saskatchewan, Canada S7N 3R2.
Neurotoxicology. 2004 Jan;25(1-2):251-66. doi: 10.1016/S0161-813X(03)00104-9.
Many inhibitors of monoamine oxidase, particularly those developed during the past three decades, are often referred to as being "selective" for one or other isoform of the enzyme. However true this may be, selectivity within the EC 1.4.3.4 family does not preclude the possibility of interactions of these drugs with other proteins unrelated to monoamine oxidase. Indeed, evidence exists which either suggests or demonstrates directly that many of these inhibitors do interact with, and affect the behaviour of, other enzymes, receptor systems and uptake pumps, with potentially interesting consequences, desirable or otherwise, for the patient or the pharmacologist. An overview of many such interactions, and speculation upon some of the possible consequences, are provided in this review.
许多单胺氧化酶抑制剂，尤其是过去三十年研发的那些，常被称为对该酶的一种或另一种同工型具有“选择性”。然而，无论这有多正确，在EC 1.4.3.4家族内的选择性并不排除这些药物与单胺氧化酶无关的其他蛋白质相互作用的可能性。确实，有证据直接或间接表明，许多此类抑制剂确实会与其他酶、受体系统和摄取泵相互作用并影响其行为，这对患者或药理学家可能产生有趣的后果，无论是有益的还是其他方面的。本综述提供了许多此类相互作用的概述，并对一些可能的后果进行了推测。
